Laboratory Medicine ›› 2025, Vol. 40 ›› Issue (2): 197-200.DOI: 10.3969/j.issn.1673-8640.2025.02.017
Previous Articles Next Articles
Received:2023-04-11
Revised:2024-07-11
Online:2025-02-28
Published:2025-03-07
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2025.02.017
| 项目 | 检测结果 | 参考区间 | 单位 |
|---|---|---|---|
| PT | 43.60 | 10.00~14.00 | s |
| APTT | 183.70 | 23.00~35.00 | s |
| Fib | 3.10 | 2.00~4.00 | g·L-1 |
| TT | 19.60 | 14.00~21.00 | s |
| LA筛查实验 | 182.50 | 31.00~44.00 | s |
| LA筛查比率 | 5.56 | % | |
| LA确诊实验 | 108.00 | 30.00~38.00 | s |
| LA确认比率 | 3.65 | % | |
| LA比率 | 1.52 | 0.80~1.20 | % |
| 凝血因子Ⅱ | 2.30 | 70.00~120.00 | % |
| 凝血因子Ⅱ 1∶4稀释 | 3.20 | 70.00~120.00 | % |
| 凝血因子Ⅴ | 47.80 | 70.00~120.00 | % |
| 凝血因子Ⅴ1∶4稀释 | 92.50 | 70.00~120.00 | % |
| 凝血因子Ⅶ | 52.60 | 70.00~120.00 | % |
| 凝血因子Ⅶ1∶4稀释 | 67.60 | 70.00~120.00 | % |
| 凝血因子Ⅷ | 3.80 | 70.00~120.00 | % |
| 凝血因子Ⅷ1∶4稀释 | 45.50 | 70.00~120.00 | % |
| 凝血因子Ⅸ | 1.80 | 70.00~120.00 | % |
| 凝血因子Ⅸ 1∶4稀释 | 28.50 | 70.00~120.00 | % |
| 凝血因子Ⅹ | 测不出 | 70.00~120.00 | % |
| 凝血因子Ⅹ1∶4稀释 | 73.30 | 70.00~120.00 | % |
| 凝血因子Ⅺ | 1.20 | 70.00~120.00 | % |
| 凝血因子Ⅺ 1∶4稀释 | 12.70 | 70.00~120.00 | % |
| 凝血因子Ⅻ | 1.10 | 70.00~120.00 | % |
| 凝血因子Ⅻ 1∶4稀释 | 7.30 | 70.00~120.00 | % |
| 项目 | 检测结果 | 参考区间 | 单位 |
|---|---|---|---|
| PT | 43.60 | 10.00~14.00 | s |
| APTT | 183.70 | 23.00~35.00 | s |
| Fib | 3.10 | 2.00~4.00 | g·L-1 |
| TT | 19.60 | 14.00~21.00 | s |
| LA筛查实验 | 182.50 | 31.00~44.00 | s |
| LA筛查比率 | 5.56 | % | |
| LA确诊实验 | 108.00 | 30.00~38.00 | s |
| LA确认比率 | 3.65 | % | |
| LA比率 | 1.52 | 0.80~1.20 | % |
| 凝血因子Ⅱ | 2.30 | 70.00~120.00 | % |
| 凝血因子Ⅱ 1∶4稀释 | 3.20 | 70.00~120.00 | % |
| 凝血因子Ⅴ | 47.80 | 70.00~120.00 | % |
| 凝血因子Ⅴ1∶4稀释 | 92.50 | 70.00~120.00 | % |
| 凝血因子Ⅶ | 52.60 | 70.00~120.00 | % |
| 凝血因子Ⅶ1∶4稀释 | 67.60 | 70.00~120.00 | % |
| 凝血因子Ⅷ | 3.80 | 70.00~120.00 | % |
| 凝血因子Ⅷ1∶4稀释 | 45.50 | 70.00~120.00 | % |
| 凝血因子Ⅸ | 1.80 | 70.00~120.00 | % |
| 凝血因子Ⅸ 1∶4稀释 | 28.50 | 70.00~120.00 | % |
| 凝血因子Ⅹ | 测不出 | 70.00~120.00 | % |
| 凝血因子Ⅹ1∶4稀释 | 73.30 | 70.00~120.00 | % |
| 凝血因子Ⅺ | 1.20 | 70.00~120.00 | % |
| 凝血因子Ⅺ 1∶4稀释 | 12.70 | 70.00~120.00 | % |
| 凝血因子Ⅻ | 1.10 | 70.00~120.00 | % |
| 凝血因子Ⅻ 1∶4稀释 | 7.30 | 70.00~120.00 | % |
| 项目 | 结果 | 参考区间 | 单位 |
|---|---|---|---|
| APTT1 | 142.70 | 23.00~35.00 | s |
| APTT2 | 23.10 | 23.00~35.00 | s |
| APTT3 | 105.30 | 23.00~35.00 | s |
| APTT4 | 159.80 | 23.00~35.00 | s |
| APTT5 | 35.70 | 23.00~35.00 | s |
| APTT6 | 124.10 | 23.00~35.00 | s |
| APTT7 | 132.40 | 23.00~35.00 | s |
| 项目 | 结果 | 参考区间 | 单位 |
|---|---|---|---|
| APTT1 | 142.70 | 23.00~35.00 | s |
| APTT2 | 23.10 | 23.00~35.00 | s |
| APTT3 | 105.30 | 23.00~35.00 | s |
| APTT4 | 159.80 | 23.00~35.00 | s |
| APTT5 | 35.70 | 23.00~35.00 | s |
| APTT6 | 124.10 | 23.00~35.00 | s |
| APTT7 | 132.40 | 23.00~35.00 | s |
| 项目 | 结果 | 参考区间 | 单位 |
|---|---|---|---|
| LA筛查实验 | 209.50 | 31.00~44.00 | s |
| LA筛查比率 | 6.39 | % | |
| LA确诊实验 | 74.30 | 30.00~38.00 | s |
| LA确认比率 | 2.51 | % | |
| LA比率 | 2.54 | 0.80~1.20 | % |
| 项目 | 结果 | 参考区间 | 单位 |
|---|---|---|---|
| LA筛查实验 | 209.50 | 31.00~44.00 | s |
| LA筛查比率 | 6.39 | % | |
| LA确诊实验 | 74.30 | 30.00~38.00 | s |
| LA确认比率 | 2.51 | % | |
| LA比率 | 2.54 | 0.80~1.20 | % |
| 项目 | 检测结果 | 参考区间 | 单位 |
|---|---|---|---|
| 巨细胞病毒抗体IgM | 20.60 | ≤22.00 | U·mL-1 |
| 单纯疱疹病毒抗体IgM | 2.50 | ≤1.10 | U·mL-1 |
| 风疹病毒抗体IgM | <10.00 | ≤25.00 | AU·mL-1 |
| 弓形体抗体IgM | <3.00 | ≤8.00 | AU·mL-1 |
| 巨细胞病毒抗体IgG | 31.20 | ≤14.00 | U·mL-1 |
| 单纯疱疹病毒抗体IgG | 3.20 | ≤1.10 | U·mL-1 |
| 风疹病毒抗体IgG | 61.70 | ≤11.00 | IU·mL-1 |
| 弓形体抗体IgG | 26.30 | ≤8.80 | IU·mL-1 |
| EB病毒核心抗原IgG | 105.00 | <20.00 | U·mL-1 |
| EB病毒衣壳抗原IgG | 22.30 | 0.00~20.00 | U·mL-1 |
| 抗β2-GPⅠ抗体 | 阳性 | 阴性 | |
| 抗心磷脂抗体 | 阳性 | 阴性 | |
| 抗双链DNA抗体 | >300.00 | 0.00~36.00 | IU·mL-1 |
| 抗核抗体 | 阳性 | 阴性 | |
| 补体3 | 313.00 | 900.00~1 800.00 | mg·L-1 |
| 补体4 | 12.00 | 100.00~400.00 | mg·L-1 |
| 血清总补体活性 | 6.30 | 23.00~56.00 | U·mL-1 |
| 项目 | 检测结果 | 参考区间 | 单位 |
|---|---|---|---|
| 巨细胞病毒抗体IgM | 20.60 | ≤22.00 | U·mL-1 |
| 单纯疱疹病毒抗体IgM | 2.50 | ≤1.10 | U·mL-1 |
| 风疹病毒抗体IgM | <10.00 | ≤25.00 | AU·mL-1 |
| 弓形体抗体IgM | <3.00 | ≤8.00 | AU·mL-1 |
| 巨细胞病毒抗体IgG | 31.20 | ≤14.00 | U·mL-1 |
| 单纯疱疹病毒抗体IgG | 3.20 | ≤1.10 | U·mL-1 |
| 风疹病毒抗体IgG | 61.70 | ≤11.00 | IU·mL-1 |
| 弓形体抗体IgG | 26.30 | ≤8.80 | IU·mL-1 |
| EB病毒核心抗原IgG | 105.00 | <20.00 | U·mL-1 |
| EB病毒衣壳抗原IgG | 22.30 | 0.00~20.00 | U·mL-1 |
| 抗β2-GPⅠ抗体 | 阳性 | 阴性 | |
| 抗心磷脂抗体 | 阳性 | 阴性 | |
| 抗双链DNA抗体 | >300.00 | 0.00~36.00 | IU·mL-1 |
| 抗核抗体 | 阳性 | 阴性 | |
| 补体3 | 313.00 | 900.00~1 800.00 | mg·L-1 |
| 补体4 | 12.00 | 100.00~400.00 | mg·L-1 |
| 血清总补体活性 | 6.30 | 23.00~56.00 | U·mL-1 |
| [1] | BACA V, MONTIEL G, MEILLÓN L, et al. Diagnosis of lupus anticoagulant in the lupus anticoagulant-hypoprothrombinemia syndrome:report of two cases and review of the literature[J]. Am J Hematol, 2002, 71(3):200-207. |
| [2] | PILANIA R K, SURI D, JINDAL A K, et al. Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus erythematosus in children:report of two cases and systematic review of the literature[J]. Rheumatol Int, 2018, 38(10):1933-1940. |
| [3] | RAPAPORT S I, AMES S B, DUVALL B J. A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity[J]. Blood, 1960,15:212-227. |
| [4] |
FLECK R A, RAPAPORT S I, RAO L V. Anti-prothrombin antibodies and the lupus anticoagulant[J]. Blood, 1988, 72(2):512-519.
PMID |
| [5] | EBERHARD A, SPARLING C, SUDBURY S, et al. Hypoprothrombinemia in childhood systemic lupus erythematosus[J]. Semin Arthritis Rheum, 1994, 24(1):12-18. |
| [6] | IEKO M, YOSHIDA M, NAITO S, et al. Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases:experiences at a single center in Japan[J]. Int J Hematol, 2019, 110(2):197-204. |
| [7] | SARKER T, ROY S, HOLLON W, et al. Lupus anticoagulant acquired hypoprothrombinemia syndrome in childhood:two distinct patterns and review of the literature[J]. Haemophilia, 2015, 21(6):754-760. |
| [8] | MAZODIER K, ARNAUD L, MATHIAN A, et al. Lupus anticoagulant-hypoprothrombinemia syndrome:report of 8 cases and review of the literature[J]. Medicine(Baltimore), 2012, 91(5):251-260. |
| [9] | MEIRELES E, MACHADO F, TELES L, et al. A case report of severe bleeding due to lupus anticoagulant hypoprothrombinemia syndrome[J]. J Thromb Thrombolysis, 2020, 49(2):334-336. |
| [10] |
KIM J S, KIM M J, BAE E Y, et al. Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome[J]. Korean J Pediatr, 2014, 57(4):202-205.
DOI PMID |
| [11] |
BAJAJ S P, RAPAPORT S I, FIERER D S, et al. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome[J]. Blood, 1983, 61(4):684-692.
PMID |
| [12] | RAFLORES M B, KAPLAN R B, SPERO J A. Pre-operative management of a patient with hypoprothrombinemia-lupus anticoagulant syndrome[J]. Thromb Haemost, 2007, 98(1):248-250. |
| [13] | CHAN E Y, LEUNG K, SOO E, et al. A Chinese boy with lupus anticoagulant-hypoprothrombinemia syndrome:a case report and review of the literature[J]. J Pediatr Hematol Oncol, 2021, 43(3):e445-e447. |
| [14] | SAKAMOTO A, OGURA M, HATTORI A, et al. Lupus anticoagulant hypoprothrombinemia syndrome associated with bilateral adrenal haemorrhage in a child:early diagnosis and intervention[J]. Thromb J, 2021, 19(1):19. |
| [15] | MALBORA B, BILALOGLU E. Lupus anticoagulant positivity pediatric patients with prolonged activated partial thromboplastin time:a single-center experience and review of literature[J]. Pediatr Hematol Oncol, 2015, 32(7):495-504. |
| [16] | MULLIEZ S M, DE KEYSER F, VERBIST C, et al. Lupus anticoagulant-hypoprothrombinemia syndrome:report of two cases and review of the literature[J]. Lupus, 2015, 24(7):736-745. |
| [17] | PASCHAL R D, NEFF A T. Resolution of hypoprothrombinemia-lupus anticoagulant syndrome(HLAS) after multidrug therapy with rituximab:a case report and review of the literature[J]. Haemophilia, 2013, 19(2):e62-e65. |
| [18] |
CETIN GEDIK K, SIDDIQUE S, AGUIAR C L. Rituximab use in pediatric lupus anticoagulant hypoprothrombinemia syndrome - report of three cases and review of the literature[J]. Lupus, 2018, 27(7):1190-1197.
DOI PMID |
| [19] | BAYRY L D. The antiinflammatory IgG[J]. N Engl J Med, 2008, 359(3):307-309. |
| [20] | PERNOD G, ARVIEUX J, CARPENTIER P H, et al. Successful treatment of lupus anticoagulant-hypoprothrombinemia syndrome using intravenous immunoglobulins[J]. Thromb Haemost, 1997, 78(2):969-970. |
| [21] |
KOCHERIL A P, VETTIYIL G I, GEORGE A S, et al. Pediatric systemic lupus erythematosus with lupus anticoagulant hypoprothrombinemia syndrome-a case series with review of literature[J]. Lupus, 2021, 30(4):641-648.
DOI PMID |
| [22] | FUJIWARA K, SHIMIZU J, TSUKAHARA H, et al. Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis:a report of Japanese sibling cases and review of the literature[J]. Rheumatol Int, 2019, 39(10):1811-1819. |
| [1] | ZHOU Jiakuan, GUO Ping, CAI Qi, YANG Mingkang, HUANG Zhixi, XUE Yilun, HUA Renxiang, LIN Han, LI Jiaming, WANG Jianbiao. Molecular epidemiological analysis of patients with increased stomatocytes and giant platelets in peripheral blood [J]. Laboratory Medicine, 2025, 40(2): 171-177. |
| [2] | WANG Chengyun, GU Ping, PAN Qiuhui, WANG Jing. Changes and clinical value of blood coagulation indexes in children with infection [J]. Laboratory Medicine, 2025, 40(2): 178-181. |
| [3] | ZHANG Lan, ZHU Jianfeng, PAN Baishen, CHEN Pu, WANG Beili, GUO Wei. Prognostic value of circulating plasma cells determined by morphology in newly diagnosed multiple myeloma [J]. Laboratory Medicine, 2025, 40(1): 15-19. |
| [4] | CUI Weiqi, OU Xinyang, ZHAO Chunhe, XIA Wei, QU Linlin. Progress of thrombin-activatable fibrinolysis inhibitor determination in clinical application [J]. Laboratory Medicine, 2024, 39(10): 1021-1026. |
| [5] | ZHU Longyin, PAN Qianguang, YANG Sha, ZENG Yuqin, FU Chunxiao, PU Youmin, FANG Jia, YAN Chunyan, ZHAO Hongwen. Early warning value of whole blood cell derived inflammatory markers for delayed graft function of renal transplantation [J]. Laboratory Medicine, 2024, 39(10): 939-944. |
| [6] | DENG Shuang, FANG Jingshu, GAN Fangyan. Predictive value of activated partial thromboplastin time，thromboelastogram and fibrin monomer in patients treated with extracorporeal membrane oxygenation for hemorrhage and thrombosis [J]. Laboratory Medicine, 2024, 39(8): 764-769. |
| [7] | ZHANG Jialing, QI Jun. Interference and correction of chylemia on blood cell analysis parameters in tumor patients [J]. Laboratory Medicine, 2024, 39(8): 770-773. |
| [8] | . [J]. Laboratory Medicine, 2024, 39(8): 807-809. |
| [9] | WANG Tiankai, LIU Lin, JIN Peipei, WANG Fang, DING Ning. Clinical value of new neutrophil parameter NEU-X，NEU-Y and NEU-Z in diagnosis of sepsis [J]. Laboratory Medicine, 2024, 39(7): 682-686. |
| [10] | . [J]. Laboratory Medicine, 2024, 39(7): 696-699. |
| [11] | ZHAO Chunhe, SHAO Huihui, CUI Weiqi, XIA Wei, QU Linlin. Progress in application of blood coagulation point-of-care testing [J]. Laboratory Medicine, 2024, 39(7): 709-714. |
| [12] | . [J]. Laboratory Medicine, 2024, 39(6): 602-607. |
| [13] | ZHOU Ruiling, ZHANG Xinyu, REN Xiaoling, ZHANG Wen, FAN Changzheng, ZHANG Qiong. Relationship between uric acid/creatinine ratio and neutrophil/lymphocyte ratio and hypoxemia in patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Laboratory Medicine, 2024, 39(5): 474-479. |
| [14] | LI Kejing, WANG Lin, YANG Ning. Relationship between NLR，TGF-β1 and Cav-1 levels and bleeding risk after mechanical thrombectomy for acute intracranial artery occlusion in elders [J]. Laboratory Medicine, 2024, 39(5): 480-484. |
| [15] | LIU Lin, WANG Tiankai, QIN Kangchunfeng, DING Ning. Correlations between monocyte-to-lymphocyte ratio with coronary heart disease and the extent of coronary atherosclerosis [J]. Laboratory Medicine, 2024, 39(5): 485-490. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
